62 related articles for article (PubMed ID: 11956668)
1. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.
Goldstein JA
Br J Clin Pharmacol; 2001 Oct; 52(4):349-55. PubMed ID: 11678778
[TBL] [Abstract][Full Text] [Related]
3. Role of genetic polymorphisms in clopidogrel response variability: a systematic review.
Lopez J; Mark J; Duarte GJ; Shaban M; Sosa F; Mishra R; Jain S; Tran A; Khizar A; Karpel D; Acosta G; Rodriguez-Guerra M
Open Heart; 2023 Nov; 10(2):. PubMed ID: 37963685
[TBL] [Abstract][Full Text] [Related]
4. CYP2C19 gene polymorphism in Ningxia.
Yang Z; Xie Y; Zhang D; Zou Y; Li X; Chen R; Zhang X; Chen S; Bai F
Pharmacol Rep; 2023 Jun; 75(3):705-714. PubMed ID: 36913175
[TBL] [Abstract][Full Text] [Related]
5. Analysis of CYP2C19 Genetic Polymorphism in a Large Ethnic Hakka Population in Southern China.
Zhong Z; Hou J; Li B; Zhang Q; Liu S; Li C; Liu Z; Yang M; Zhong W; Zhao P
Med Sci Monit; 2017 Dec; 23():6186-6192. PubMed ID: 29288619
[TBL] [Abstract][Full Text] [Related]
6. Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors.
Deshpande N; V S; V V RK; H V V M; M S; Banerjee R; Tandan M; D NR
Meta Gene; 2016 Sep; 9():159-64. PubMed ID: 27419077
[TBL] [Abstract][Full Text] [Related]
7. Genotype‑phenotype analysis of CYP2C19 in the Tibetan population and its potential clinical implications in drug therapy.
Jin T; Zhang X; Geng T; Shi X; Wang L; Yuan D; Kang L
Mol Med Rep; 2016 Mar; 13(3):2117-23. PubMed ID: 26781306
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms and phenotypic analysis of drug-metabolizing enzyme CYP2C19 in a Li Chinese population.
Ding Y; Xu D; Zhang X; Yang H; Geng T; He P; Yao J; Yi S; Xu H; Wu D; Wang X; Jin T
Int J Clin Exp Pathol; 2015; 8(10):13201-8. PubMed ID: 26722519
[TBL] [Abstract][Full Text] [Related]
9. Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.
Fricke-Galindo I; Céspedes-Garro C; Rodrigues-Soares F; Naranjo ME; Delgado Á; de Andrés F; López-López M; Peñas-Lledó E; LLerena A
Pharmacogenomics J; 2016 Apr; 16(2):113-23. PubMed ID: 26503820
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the CYP2C19 genetic polymorphism in Han and Uyghur patients with cardiovascular and cerebrovascular diseases in the Kashi area of Xinjiang.
Li Y; Yang H; Zou X; Xiong L; Li Z; Luo J; Zhao B; Liu W; Du X
Med Sci Monit; 2014 Nov; 20():2213-8. PubMed ID: 25381554
[TBL] [Abstract][Full Text] [Related]
11. CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors.
Sukasem C; Tunthong R; Chamnanphon M; Santon S; Jantararoungtong T; Koomdee N; Prommas S; Puangpetch A; Vathesatogkit P
Pharmgenomics Pers Med; 2013; 6():85-91. PubMed ID: 24019752
[TBL] [Abstract][Full Text] [Related]
12. Functional polymorphisms in the CYP2C19 gene contribute to digestive system cancer risk: evidence from 11,042 subjects.
Zhou B; Song Z; Qian M; Li L; Gong J; Zou S
PLoS One; 2013; 8(7):e66865. PubMed ID: 23874401
[TBL] [Abstract][Full Text] [Related]
13. Quantitative assessment of the influence of cytochrome P450 2C19 gene polymorphisms and digestive tract cancer risk.
Yao L; Wang HC; Liu JZ; Xiong ZM
Tumour Biol; 2013 Oct; 34(5):3083-91. PubMed ID: 23754447
[TBL] [Abstract][Full Text] [Related]
14. Relative Copy Number Variations of CYP2C19 in South Indian Population.
Devendran A; Uppugunduri CR; Sundaram R; Shewade DG; Rajagopal K; Chandrasekaran A
Mol Biol Int; 2012; 2012():643856. PubMed ID: 22792463
[TBL] [Abstract][Full Text] [Related]
15. Functional characterization of promoter region polymorphisms of human CYP2C19 gene.
Satyanarayana Chakradhara Rao U; Devendran A; Satyamoorthy K; Shewade DG; Krishnamoorthy R; Chandrasekaran A
Mol Biol Rep; 2011 Aug; 38(6):4171-9. PubMed ID: 21152987
[TBL] [Abstract][Full Text] [Related]
16. Implementing genotype-guided antithrombotic therapy.
Seip RL; Duconge J; Ruaño G
Future Cardiol; 2010 May; 6(3):409-24. PubMed ID: 20462345
[TBL] [Abstract][Full Text] [Related]
17. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.
Wang G; Lei HP; Li Z; Tan ZR; Guo D; Fan L; Chen Y; Hu DL; Wang D; Zhou HH
Eur J Clin Pharmacol; 2009 Mar; 65(3):281-5. PubMed ID: 18982321
[TBL] [Abstract][Full Text] [Related]
18. Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity.
Klaassen T; Jetter A; Tomalik-Scharte D; Kasel D; Kirchheiner J; Jaehde U; Fuhr U
Eur J Clin Pharmacol; 2008 Apr; 64(4):387-98. PubMed ID: 18071681
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study.
Bravo-Villalta HV; Yamamoto K; Nakamura K; Bayá A; Okada Y; Horiuchi R
Eur J Clin Pharmacol; 2005 May; 61(3):179-84. PubMed ID: 15776277
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
